SMAD3 and fibrosis: In animalstudies, empagliflozin exhibited the ability to mitigate cardiac fibrosis in itsinitial stages following an AMI, through the inhibition of thetransforming growth factor-β1 (TGF-β1)/Smad3 fibrosis pathway, unrelated to the medication’s hemodynamiceffects.